Purpose: Neuroinflammatory mechanisms are associated with fatigue in neurodegenerative conditions such as Parkinson's. The symptoms in Parkinson's including fatigue are thought to be related to a-synuclein overexpression. This study investigated genomic correlates of fatigue experienced by men with prostate cancer receiving external beam radiation therapy (EBRT). Patients and methods: Sixteen men with non-metastatic prostate cancer who were scheduled to receive EBRT were enrolled. Fatigue scores and blood were obtained at baseline (prior to EBRT, D0); one hour following initiation of EBRT (D1), day 7 (D7), day 14 (D14), midpoint (days 19-21, D21), completion (days 38-42, D42), and four weeks post-EBRT (days 68-72, D72). Gene expression profiling using microarray analysis was performed from peripheral blood and confirmatory qPCR and protein (ELISA) analyses verified the microarray results. Correlations between fatigue and gene/protein expressions were determined using a mixed model approach. Results: Microarray data showed significant, differential expression of 463 probesets following EBRT. SNCA had a 2.95-fold change at D21from baseline. SNCA expression was confirmed by qPCR (p < 0.001) and ELISA (p < 0.001) over time during EBRT. Fatigue scores were significantly correlated with SNCA gene expression on D14 (r = 0.55, p < 0.05) and plasma a-synuclein concentrations on D42 of EBRT (r = 0.54, p = 0.04).
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Results: Microarray data showed significant, differential expression of 463 probesets following EBRT. SNCA had a 2.95-fold change at D21from baseline. SNCA expression was confirmed by qPCR (p < 0.001) and ELISA (p < 0.001) over time during EBRT. Fatigue scores were significantly correlated with SNCA gene expression on D14 (r = 0.55, p < 0.05) and plasma a-synuclein concentrations on D42 of EBRT (r = 0.54, p = 0.04).
Conclusion:
Fatigue experienced during EBRT may be mediated by a-synuclein overexpression. Alphasynuclein may serve as a useful biomarker to understand the mechanisms and pathways related to the development of fatigue in this population.
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Introduction
Localized radiation therapy is one of the main therapeutic options recommended for the management of non-metastatic prostate cancer (Thompson et al., 2007) . Advances in prostate cancer treatment using improved techniques in the delivery of localized therapy such as external beam radiation therapy (EBRT) have led to high cure rates and prolonged the natural history of the disease. However, the improved survival rates are mitigated by the toxicities associated with these treatments that lower the quality of life for survivors. Fatigue is one of the most commonly reported and the most distressing side effect reported in the radiation therapy setting, affecting approximately 78% (range = 31-100%) of patients receiving localized radiation therapy (Greenberg et al., 1992; Smets et al., 1998) . It is also the most common baseline symptom noted in men with prostate cancer referred for a curative course of radiation therapy (Danjoux et al., 2007 ) and one of the major indicators of cancer therapeutic outcomes (Monga et al., 1999) . Fatigue severity of most men with prostate cancer is known to increase significantly during the course of radiation therapy peaking at midpoint and declining after completion of therapy (Miaskowski et al., 2008) . The etiology of fatigue progression and severity while receiving cancer treatment is currently unknown. However, neuroinflammation has been reported to be related to fatigue in other conditions (Bokemeyer et al., 2011; Rönnbäck and Hansson, 2004) .
Although the National Comprehensive Cancer Network (NCCN) practice guidelines recommend the use of methylphenidate as a
